Abstract TP253: Clopidogrel Pharmacogenetics in the POINT Trial

Introduction: Across 269 international sites, the POINT trial randomly assigned 4881 patients with minor ischemic stroke or high-risk transient ischemic attack to receive either clopidogrel at a lo...